Phase II study to evaluate the efficacy and safety of Herceptin in combination with XELOX as first-line treatment for advanced or metastatic gastric cancer patients with HER2-positive tumors.
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2015
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Trastuzumab (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms HerXO
- 26 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jan 2012 Planned End Date changed from 6 Jul 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.
- 03 Jan 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.